Current Diabetes Reports

, 11:543

The Molecular Genetics of Sulfonylurea Receptors in the Pathogenesis and Treatment of Insulin Secretory Disorders and Type 2 Diabetes

Genetics (Jose C. Florez, Section Editor)

Abstract

Sulfonylurea receptors (SURs) form an integral part of the ATP-sensitive potassium (KATP) channel complex that is present in most excitable cell types. KATP channels couple cellular metabolism to electrical activity and provide a wide range of cellular functions including stimulus secretion coupling in pancreatic β cells. KATP channels are composed of SURs and inward rectifier potassium channel (Kir6.x) subunits encoded by the ABCC8/9 and KCNJ8/11 genes, respectively. Recent advances in the genetics, molecular biology, and pharmacology of SURs have led to an increased understanding of these channels in the etiology and treatment of rare genetic insulin secretory disorders. Furthermore, common genetic variants in these genes are associated with an increased risk for type 2 diabetes. In this review we summarize the molecular biology, pharmacology, and physiology of SURs and KATP channels, highlighting recent advances in their genetics and understanding of rare insulin secretory disorders and susceptibility to type 2 diabetes.

Keywords

Sulfonylurea receptor KATP channel Pharmacology Monogenic mutations Genetic variants Insulin secretory disorder Type 2 diabetes 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Noma A. ATP-regulated K+channels in cardiac muscle. Nature. 1983;305(5930):147–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Ashcroft FM, Harrison DE, Ashcroft SJH. Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells. Nature. 1984;312(5993):446–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Aguilar-Bryan L et al. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science. 1995;268(5209):423–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Inagaki N et al. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science. 1995;270(5239):1166–70.PubMedCrossRefGoogle Scholar
  5. 5.
    Nichols CG. KATP channels as molecular sensors of cellular metabolism. Nature. 2006;440(7083):470–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Ashcroft FM, Gribble FM. ATP-sensitive K+channels and insulin secretion: their role in health and disease. Diabetologia. 1999;42(8):903–19.PubMedCrossRefGoogle Scholar
  7. 7.
    Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes. 2000;49(11):1751–60.PubMedCrossRefGoogle Scholar
  8. 8.
    Aguilar-Bryan L, Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr Rev. 1999;20(2):101–35.PubMedCrossRefGoogle Scholar
  9. 9.
    Clement JP et al. Association and stoichiometry of K(ATP) channel subunits. Neuron. 1997;18(5):827–38.PubMedCrossRefGoogle Scholar
  10. 10.
    Gribble FM, Reimann F. Sulphonylurea action revisited: the post-cloning era. Diabetologia. 2003;46(7):875–91.PubMedCrossRefGoogle Scholar
  11. 11.
    Flagg TP et al. Differential structure of atrial and ventricular KATP: atrial KATP channels require SUR1. Circ Res. 2008;103(12):1458–65.PubMedCrossRefGoogle Scholar
  12. 12.
    •• Schmid D, et al. An abundant, truncated human sulfonylurea receptor 1 splice variant has prodiabetic properties and impairs sulfonylurea action. Cell Mol Life Sci. 2011. p. 1–20. This study identifies a novel abundant splice variant of the SUR1 subunit found in cardiac, pancreatic, and other tissues of human origin, but not in rat tissues. This splice variant encodes a truncated peptide lacking exon 2 that substantially changes the functional properties of K ATP channels such that it represented an endogenous K ATP -channel modulator with prodiabetic properties in islet cells.Google Scholar
  13. 13.
    •• Hund TJ, Mohler PJ. Differential roles for SUR subunits in KATP channel membrane targeting and regulation. Am J Physiol Heart Circ Physiol. 2011;300(1):H33–5. This paper reviews the molecular composition, function, and regulation of the K ATP channel in the heart. PubMedCrossRefGoogle Scholar
  14. 14.
    •• Kang Y, et al. ATP modulates interaction of syntaxin-1A with sulfonylurea receptor 1 to regulate pancreatic β-cell KATP channels. J Biol Chem. 2011;286(7):5876–83. K ATP channels can be regulated by a variety of membrane-bound proteins. This paper indicates that the SNARE protein syntaxin-1A independently inhibits K ATP channel gating, which provides the evidence that K ATP channel activity can be regulated via ATP modulation of SNARE protein binding to the SUR1 subunit. PubMedCrossRefGoogle Scholar
  15. 15.
    Kikuta T et al. Docking and fusion of insulin secretory granules in SUR1 knock out mouse [beta]-cells observed by total internal reflection fluorescence microscopy. FEBS Lett. 2005;579(7):1602–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Nichols CG et al. Adenosine diphosphate as an intracellular regulator of insulin secretion. Science. 1996;272(5269):1785–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Terzic A, Jahangir A, Kurachi Y. Cardiac ATP-sensitive K+channels: regulation by intracellular nucleotoides and K+channel-opening drugs. Am J Physiol. 1995;269:C525–45.PubMedGoogle Scholar
  18. 18.
    • de Wet H, et al. The ATPase activities of sulfonylurea receptor 2A and sulfonylurea receptor 2B are influenced by the C-terminal 42 amino acids. FEBS J. 2010;277(12):2654–62. SUR isoforms possess different ATPase activities. This paper shows that the last 42 amino acids from NBD2 at the C-terminus of SUR2 are responsible for the different ATPase activities of SUR2A and SUR2A.PubMedCrossRefGoogle Scholar
  19. 19.
    Bienengraeber M et al. ATPase activity of the sulfonylurea receptor: a catalytic function for the KATP channel complex. FASEB J. 2000;14(13):1943–52.PubMedCrossRefGoogle Scholar
  20. 20.
    • Akrouh A, et al. Molecular biology of KATPchannels and implications for health and disease. IUBMB Life 2009;61(10):971–8. This paper reviews the current understanding of the molecular biology, pharmacology, and physiology of K ATP channels and the disease states that result from aberrant expression or function of these proteins with a special focus on the pancreas and the cardiovascular system. PubMedCrossRefGoogle Scholar
  21. 21.
    Light PE et al. Molecular basis of protein kinase C-induced activation of ATP-sensitive potassium channels. Proc Natl Acad Sci. 2000;97(16):9058–63.PubMedCrossRefGoogle Scholar
  22. 22.
    Light PE et al. Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein Kinase A- and ADP-dependent mechanism. Mol Endocrinol. 2002;16(9):2135–44.PubMedCrossRefGoogle Scholar
  23. 23.
    Light PE et al. Protein kinase C–induced changes in the stoichiometry of ATP binding activate cardiac ATP-sensitive K+channels: a possible mechanistic link to ischemic preconditioning. Circ Res. 1996;79(3):399–406.PubMedGoogle Scholar
  24. 24.
    Masia R, Enkvetchakul D, Nichols CG. Differential nucleotide regulation of KATP channels by SUR1 and SUR2A. J Mol Cell Cardiol. 2005;39(3):491–501.PubMedCrossRefGoogle Scholar
  25. 25.
    Riedel MJ et al. Kir6.2 polymorphisms sensitize beta-cell ATP-sensitive potassium channels to activation by acyl CoAs: a possible cellular mechanism for increased susceptibility to type 2 diabetes. Diabetes. 2003;52(10):2630–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Riedel MJ, Light PE. Saturated and cis/trans unsaturated acyl CoA esters differentially regulate wild-type and polymorphic beta-cell ATP-sensitive K+channels. Diabetes. 2005;54(7):2070–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Yaney GC, Corkey BE. Fatty acid metabolism and insulin secretion in pancreatic beta cells. Diabetologia. 2003;46(10):1297–312.PubMedCrossRefGoogle Scholar
  28. 28.
    Duhault J, Lavielle R. History and evolution of the concept of oral therapy in diabetes. Diabetes Res Clin Pract. 1991;14 Suppl 2:S9–13.PubMedCrossRefGoogle Scholar
  29. 29.
    Feldman JM. Glyburide: a second-generation sulfonylurea hypoglycemic agent. History, chemistry, metabolism, pharmacokinetics, clinical use and adverse effects. Pharmacotherapy. 1985;5(2):43–62.PubMedGoogle Scholar
  30. 30.
    Trube G, Rorsman P, Ohno-Shosaku T. Opposite effects of tolbutamide and diazoxide on the ATP-dependent K+channel in mouse pancreatic beta-cells. Pflügers Archiv—Eur J Physiol. 1986;407(5):493–9.CrossRefGoogle Scholar
  31. 31.
    Sturgess NC et al. The sulphonylurea receptor may be an ATP-sensitive potassium channel. Lancet. 1985;2(8453):474–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Nelson DA, Aguilar-Bryan L, Bryan J. Specificity of photolabeling of beta-cell membrane proteins with an 125I-labeled glyburide analog. J Biol Chem. 1992;267(21):14928–33.PubMedGoogle Scholar
  33. 33.
    Malaisse WJ. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol. 2003;2(6):401–14.PubMedCrossRefGoogle Scholar
  34. 34.
    Blickle JF. Meglitinide analogues: a review of clinical data focused on recent trials. Diabetes Metab. 2006;32(2):113–20.PubMedCrossRefGoogle Scholar
  35. 35.
    McLeod JF. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clin Pharmacokinet. 2004;43(2):97–120.PubMedCrossRefGoogle Scholar
  36. 36.
    Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs. 2001;61(11):1625–60.PubMedCrossRefGoogle Scholar
  37. 37.
    • Phillippe HM, Wargo KA. Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2010;44(10):1615–23. This article reviews publications regarding the pharmacology, pharmacokinetics, efficacy, and safety of rapid-acting mitiglinide to determine its potential place in therapy for patients with T2D.PubMedCrossRefGoogle Scholar
  38. 38.
    Vila-Carriles WH, Zhao G, Bryan J. Defining a binding pocket for sulfonylureas in ATP-sensitive potassium channels. FASEB J. 2007;21(1):18–25.PubMedCrossRefGoogle Scholar
  39. 39.
    Winkler M et al. Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A+B-site ligands. J Pharmacol Exp Ther. 2007;322(2):701–8.PubMedCrossRefGoogle Scholar
  40. 40.
    •• Olson TM, Terzic A. Human KATP channelopathies: diseases of metabolic homeostasis. Pflügers Archiv—Eur J Physiol. 2010;460(2):295–306. This paper reviews the pathogenic mutations in K ATP channels that have been identified in PHHI, neonatal diabetes mellitus, atrial fibrillation, and dilated cardiomyopathy.CrossRefGoogle Scholar
  41. 41.
    •• Lang V, Light P. The molecular mechanisms and pharmacotherapy of ATP-sensitive potassium channel gene mutations underlying neonatal diabetes. Pharmacogenomics Pers Med. 2010;3:145–61. This review focuses on the molecular and cellular mechanisms of mutations in the K ATP channel that underlie ND. Sulfonylurea pharmacogenomics for ND patients are discussed with respect to evaluating whether patients with certain K ATP channel activation mutations can be successfully switched to sulfonylurea therapy.Google Scholar
  42. 42.
    Tammaro P et al. A Kir6.2 mutation causing severe functional effects in vitro produces neonatal diabetes without the expected neurological complications. Diabetologia. 2008;51(5):802–10.PubMedCrossRefGoogle Scholar
  43. 43.
    •• Clark RH, et al. Muscle dysfunction caused by a KATP channel mutation in neonatal diabetes is neuronal in origin. Science 2010;329(5990):458–61. This study showed that analogous motor impairments in the DEND syndrome originated in the CNS rather than in muscle or peripheral nerves by using mice carrying a Kir6.2 mutation (V59M) found in patients with the DEND syndrome. These findings suggested that neuronal K ATP channels should be targeted in the DEND syndrome and these K ATP channel inhibitors required high blood–brain barrier permeability.PubMedCrossRefGoogle Scholar
  44. 44.
    •• Reyes S, et al. KATP channel Kir6.2 E23K variant overrepresented in human heart failure is associated with impaired exercise stress response. Hum Genet. 2009;126(6):779–89. Blunted heart rate during exercise is a risk factor for mortality in patients with heart failure, and the common E23K polymorphism in the KCNJ11 gene is present in heart failure patients. This study establishes that patients with the homozygous KK genotype have an abnormal response to exercise as demonstrated by a blunted heart rate elevation during cardiorespiratory treadmill stress testing.PubMedCrossRefGoogle Scholar
  45. 45.
    de Wet H et al. Increased ATPase activity produced by mutations at arginine-1380 in nucleotide-binding domain 2 of ABCC8 causes neonatal diabetes. Proc Natl Acad Sci. 2007;104(48):18988–92.PubMedCrossRefGoogle Scholar
  46. 46.
    Gloyn AL et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med. 2004;350(18):1838–49.PubMedCrossRefGoogle Scholar
  47. 47.
    Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes. 2005;54(9):2503–13.PubMedCrossRefGoogle Scholar
  48. 48.
    Babenko AP et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med. 2006;355(5):456–66.PubMedCrossRefGoogle Scholar
  49. 49.
    Pearson ER et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 2006;355(5):467–77.PubMedCrossRefGoogle Scholar
  50. 50.
    Mlynarski W et al. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11. Nat Clin Pract Neurol. 2007;3(11):640–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Sagen JV et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes. 2004;53(10):2713–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Riedel MJ, Steckley DC, Light PE. Current status of the E23K Kir6.2 polymorphism: implications for type-2 diabetes. Hum Genet. 2004;116(3):133–45.PubMedCrossRefGoogle Scholar
  53. 53.
    Gloyn AL et al. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes. 2003;52(2):568–72.PubMedCrossRefGoogle Scholar
  54. 54.
    Alsmadi O et al. Genetic study of Saudi diabetes (GSSD): significant association of the KCNJ11 E23K polymorphism with type 2 diabetes. Diabetes Metab Res Rev. 2008;24(2):137–40.PubMedCrossRefGoogle Scholar
  55. 55.
    Palmer ND et al. Association of the Kir6.2 E23K variant with reduced acute insulin response in African-Americans. J Clin Endocrinol Metab. 2008;93(12):4979–83.PubMedCrossRefGoogle Scholar
  56. 56.
    Doi Y et al. Impact of Kir6.2 E23K polymorphism on the development of type 2 diabetes in a general Japanese population: The Hisayama Study. Diabetes. 2007;56(11):2829–33.PubMedCrossRefGoogle Scholar
  57. 57.
    • Zhou D, et al. The E23K variation in the KCNJ11 gene is associated with type 2 diabetes in Chinese and East Asian population. J Hum Genet. 2009;54(7):433–5. The common KCNJ11 E23K variant has been reported to be associated with T2D in various European-descent populations. This study confirms that the E23K variant is also associated with T2D susceptibility in East Asian populations.PubMedCrossRefGoogle Scholar
  58. 58.
    Florez JC et al. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes. 2004;53(5):1360–8.PubMedCrossRefGoogle Scholar
  59. 59.
    •• Hamming KSC, et al. Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel. Diabetes 2009;58(10):2419–24. This study indicates that the ABCC8 S1369A variant alters the properties of the K ATP channel that may contribute to the increased risk for T2D associated with the K23/A1369 risk haplotype. Moreover, the increased sensitivity of the K23/A1369 variant to the A-site sulfonylurea drug gliclazide (afforded by the ABCC8 A1369 risk allele) could provide a pharmacogenomic therapeutic approach for patients with T2D who are homozygous for both K23/A1369 risk alleles.PubMedCrossRefGoogle Scholar
  60. 60.
    Masia R, Nichols CG. Functional clustering of mutations in the dimer interface of the nucleotide binding folds of the sulfonylurea receptor. J Biol Chem. 2008;283(44):30322–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Sakura H et al. Sequence variations in the human Kir6.2 gene, a subunit of the beta-cell ATP-sensitive K-channel: no association with NIDDM in while Caucasian subjects or evidence of abnormal function when expressed in vitro. Diabetologia. 1996;39(10):1233–6.PubMedCrossRefGoogle Scholar
  62. 62.
    • Holstein A, et al. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes. Horm Metab Res. 2009;41(5):387–90. As pharmacogenetic factors could be of critical importance for the risk of sulfonylurea-induced hypoglycemia, this study suggests that patients with T2D carrying the K variant of the E23K polymorphism in KCNJ11 possess a reduced response to sulfonylurea therapy (glibenclamide), which results in increased hemoglobin A 1c and consequently a lower risk for sulfonylurea-induced hypoglycemia.PubMedCrossRefGoogle Scholar
  63. 63.
    Sesti G et al. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5′-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91(6):2334–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Feng Y et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care. 2008;31(10):1939–44.PubMedCrossRefGoogle Scholar
  65. 65.
    •• Carling D, et al. AMP-activated protein kinase: nature’s energy sensor. Nat Chem Biol. 2011;7(8):512–8. This paper reviews the role of AMP-activated protein kinase (AMPK) as an energy sensor and considers the recent finding that ADP, as well as AMP, activates mammalian AMPK.PubMedCrossRefGoogle Scholar
  66. 66.
    • Lee Y, et al. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 2011;60(2):391–7. This study shows that blocking glucagon action, by genetic ablation of the glucagon receptor, prevents hypoglycemia in a mouse model of type 1 diabetes.PubMedCrossRefGoogle Scholar
  67. 67.
    MacDonald PE et al. A KATP channel-dependent pathway within α cells regulates glucagon release from both rodent and human islets of langerhans. PLoS Biol. 2007;5(6):e143.PubMedCrossRefGoogle Scholar
  68. 68.
    Rorsman P et al. KATP-channels and glucose-regulated glucagon secretion. Trends Endocrinol Metab. 2008;19(8):277–84.PubMedCrossRefGoogle Scholar
  69. 69.
    Crawford RM et al. Creatine kinase is physically associated with the cardiac ATP-sensitive k+channel in vivo. FASEB J. 2002;16(1):102–4.PubMedGoogle Scholar
  70. 70.
    Krippeit-Drews P et al. Phosphocreatine as a determinant of K(ATP) channel activity in pancreatic beta-cells. Pflügers Archiv Eur J Physiol. 2003;445(5):556–62.Google Scholar
  71. 71.
    Carrasco AJ et al. Adenylate kinase phosphotransfer communicates cellular energetic signals to ATP-sensitive potassium channels. Proc Natl Acad Sci. 2001;98(13):7623–8.PubMedCrossRefGoogle Scholar
  72. 72.
    •• Alekseev AE, et al. Sarcolemmal ATP-sensitive K+ channels control energy expenditure determining body weight. Cell Metab. 2010;11(1):58–69. This study is the first demonstration that genetic disruption of K ATP channel function in the heart and skeletal muscles raises overall body energy expenditure, and generates a lean phenotype resistant to high fat diet–induced obesity with compromised physical endurance.PubMedCrossRefGoogle Scholar
  73. 73.
    • Chang TJ, et al. Serine-385 phosphorylation of inwardly rectifying K + channel subunit (Kir6.2) by AMP-dependent protein kinase plays a key role in rosiglitazone-induced closure of the K(ATP) channel and insulin secretion in rats. Diabetologia 2009;52(6):1112–21. This study reports that rosiglitazone-stimulated insulin secretion occurs through PI3K-dependent activation of AMPK and subsequent inhibition of the K ATP channel current. This study also shows that K ATP channel activity is regulated by AMPK-mediated phosphorylation of the Ser385 residue of the Kir6.2 subunit in pancreatic β cells.PubMedCrossRefGoogle Scholar
  74. 74.
    •• Lim A, et al. Glucose deprivation regulates KATP channel trafficking via AMP-activated protein kinase in pancreatic β-cells. Diabetes 2009;58(12):2813–9. This study shows a direct association between the activation of AMPK in response to glucose deprivation and increase in the cell surface expression of K ATP channels. This increase in trafficking of K ATP channels to the cell surface increases K ATP conductance, which may play a key role in inhibiting insulin secretion under low energy status.PubMedCrossRefGoogle Scholar
  75. 75.
    Florez JC et al. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes. 2007;56(2):531–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Veronica Lang
    • 1
  • Nermeen Youssef
    • 1
  • Peter E. Light
    • 1
  1. 1.Department of Pharmacology, Alberta Diabetes Institute and Cardiovascular Research CentreUniversity of AlbertaEdmontonCanada

Personalised recommendations